News | December 27, 2022
Hetero's COVID-19 oral drug gets WHO prequalification
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
Colorectal Cancer Screening is now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
They will commercialize molnupiravir in the international markets
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
